- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Malvern Today
By the People, for the People
Neuronetics Reports Q1 Earnings Results
The medical device company beat analyst estimates for the quarter.
Mar. 17, 2026 at 1:12pm
Got story updates? Submit your updates here. ›
Neuronetics, a commercial-stage medical technology company that develops non-invasive neuromodulation therapies, reported its first quarter financial results on Tuesday. The company reported a loss of $0.10 per share, beating the consensus estimate of a $0.12 loss per share. Neuronetics also reported revenue of $41.78 million, exceeding analyst expectations of $40.84 million.
Why it matters
Neuronetics' NeuroStar Advanced Therapy System, which uses repetitive transcranial magnetic stimulation (rTMS) to treat major depressive disorder, is the company's flagship product. Strong financial performance could indicate growing adoption and demand for the company's technology in the psychiatric treatment market.
The details
For the quarter, Neuronetics reported a net loss of $5.9 million, or $0.10 per share, compared to a net loss of $7.3 million, or $0.12 per share, in the same period a year ago. Revenue for the quarter came in at $41.78 million, up from $40.84 million in the prior year quarter. The company attributed the revenue growth to increased demand for its NeuroStar Advanced Therapy System.
- Neuronetics reported its Q1 2026 financial results on Tuesday, March 17, 2026.
The players
Neuronetics
A commercial-stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders.
NeuroStar Advanced Therapy System
Neuronetics' flagship product that uses repetitive transcranial magnetic stimulation (rTMS) to treat major depressive disorder.
The takeaway
Neuronetics' better-than-expected Q1 results suggest growing demand for its NeuroStar Advanced Therapy System, a non-invasive treatment for major depressive disorder. As the company continues to advance its neuromodulation technology, its financial performance will be closely watched by investors and the psychiatric treatment industry.
